INAVO120 trial shows inavolisib, palbociclib, and fulvestrant significantly improved overall survival in PIK3CA-mutant ...

Despite its expensive valuation and declining estimates, we suggest investors hold LLY stock as the company boasts solid ...

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule ...

BOULDER, Colo., May 06, 2025 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines in oncology, today ...

We designed OKI-219 and our ongoing PIKture-01 trial to set a high bar for achieving considerable selectivity in targeting oncogenic PI3Kα H1047R. Late last year, we announced preliminary data ...

The highlights included a potent KRAS inhibitor with impressive tumor growth inhibition in mouse models, a novel PI3Kα inhibitor demonstrating efficacy against key mutations, and a selective ...

The Q1 2025 charges primarily related to the acquisition of Scorpion Therapeutics, Inc.'s PI3Kα inhibitor program STX-478. The effective tax rate was 20.2% in Q1 2025 compared with 11.6% in Q1 ...

Lilly also announced in January that it would be expanding its oncology pipeline by acquiring Scorpion Therapeutics’ PI3Kα inhibitor programme in a deal worth up to $2.5bn, and partnered with Alchemab ...

Lead optimization of this series is ongoing. Cogent is developing a potential best-in-class, wild-type-sparing, PI3Kα inhibitor that provides coverage for the both the H1047R mutation as well as ...